熱門資訊> 正文
施罗德因放弃白血病候选药物而下降16%
2025-08-14 20:55
- Schrodinger (NASDAQ:SDGR) has fallen ~16% in premarket trading Thursday after announcing it would end development of SGR-2921 for relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes following the deaths of two AML patients in a trial.
- The CDC7 inhibitor was in a phase 1 dose escalation study.
- The company said that there were "two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML." As a result, further development as a combination treatment "would be difficult to pursue."
More on Schrödinger
- Schrödinger, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript
- Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results
- Schrödinger maintains 10–15% software revenue growth guidance while advancing SGR-1505 clinical program
- Schrödinger Q2 2025 Earnings Preview
推薦文章
一周財經日曆丨降息信號將定？下周全球央行年會成關鍵；小米、泡泡瑪特、快手領銜港股財報潮
港股周報丨見證歷史！南向資金單日瘋狂買入港股359億港元；騰訊績后股價一度升破600港元
特朗普政府據悉考慮動用芯片法案資金來入股英特爾
美股機會日報丨「恐怖數據」符合預期，交易員下調美聯儲降息預期；巴菲特Q2新建倉股飆升，聯合健康盤前漲超10%
銀諾醫藥-B上市首日暴漲285%，一手賺超1萬港元
投資大佬Tepper減持阿里巴巴、京東等 買入股價暴跌的聯合健康
伯克希爾減持蘋果股份 增持聯合健康集團
8月15日外盤頭條：特朗普政府洽購英特爾股份 貝森特否認推動降息 蘋果重新設計Apple Watch血氧功能
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
